ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Apatinib Combined with Vinorelbine in Second Line Treatment Failure Non-Driver Mutation Advanced Non-Small Cell Lung Cancer(VICTOR): A Phase 2, Single-Arm, Prospective Study
SSRN Electronic Journal
◽
10.2139/ssrn.3391199
◽
2019
◽
Author(s):
Xiangyu Zhang
◽
Yi Xiong
◽
Qing Xia
◽
Fang Wu
◽
Lingli Liu
◽
...
Keyword(s):
Lung Cancer
◽
Treatment Failure
◽
Prospective Study
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Small Cell
◽
Line Treatment
◽
Second Line
◽
Phase 2
◽
Small Cell Lung
Download Full-text
Related Documents
Cited By
References
88P Feasibility of outpatient dinutuximab (D) and irinotecan (I) for second-line treatment of relapsed or refractory small cell lung cancer (RR SCLC): Part 1 of an open-label, randomized, phase 2/3 study
Journal of Thoracic Oncology
◽
10.1016/s1556-0864(18)30363-0
◽
2018
◽
Vol 13
(4)
◽
pp. S48-S49
◽
Cited By ~ 3
Author(s):
M.J. Edelman
◽
O. Juan
◽
A. Navarro
◽
G. Golden
◽
A. Saunders
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Small Cell
◽
Line Treatment
◽
Second Line
◽
Phase 2
◽
Small Cell Lung
◽
Open Label
◽
Randomized Phase 2
Download Full-text
ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC)
Cancer
◽
10.1002/cncr.31779
◽
2018
◽
Vol 124
(24)
◽
pp. 4667-4675
◽
Cited By ~ 3
Author(s):
Daniel Morgensztern
◽
Manuel Cobo
◽
Santiago Ponce Aix
◽
Pieter E. Postmus
◽
Conrad R. Lewanski
◽
...
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Small Cell
◽
Line Treatment
◽
Second Line
◽
Phase 2
◽
Small Cell Lung
◽
Phase 2 Study
◽
Randomized Phase 2
Download Full-text
A two-part, open-label, randomized, phase 2/3 study of dinutuximab and irinotecan versus irinotecan for second-line treatment of subjects with relapsed or refractory small cell lung cancer.
Journal of Clinical Oncology
◽
10.1200/jco.2018.36.15_suppl.tps8588
◽
2018
◽
Vol 36
(15_suppl)
◽
pp. TPS8588-TPS8588
◽
Cited By ~ 2
Author(s):
Martin J. Edelman
◽
Oscar Juan
◽
Alejandro Navarro
◽
Gil Golden
◽
Erick Borg
◽
...
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Small Cell
◽
Line Treatment
◽
Second Line
◽
Phase 2
◽
Small Cell Lung
◽
Open Label
◽
Randomized Phase 2
Download Full-text
Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non–Small Cell Lung Cancer After Second-Line Treatment Failure
JAMA Network Open
◽
10.1001/jamanetworkopen.2020.1226
◽
2020
◽
Vol 3
(3)
◽
pp. e201226
Author(s):
Xiangyu Zhang
◽
Yi Xiong
◽
Qing Xia
◽
Fang Wu
◽
Lingli Liu
◽
...
Keyword(s):
Lung Cancer
◽
Treatment Failure
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Small Cell
◽
Line Treatment
◽
Second Line
◽
Efficacy And Safety
◽
Wild Type
◽
Small Cell Lung
Download Full-text
P76.36 A Phase 2 Study of Anlotinib Combined with Pemetrexed-Platinum (PP) as Second-Line Treatment in EGFR-Positive Non-Small Cell Lung Cancer (NSCLC)
Journal of Thoracic Oncology
◽
10.1016/j.jtho.2021.01.1093
◽
2021
◽
Vol 16
(3)
◽
pp. S602
Author(s):
J. Li
◽
J. Ge
◽
Y. Tian
◽
Y. Yang
◽
M. Zheng
◽
...
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Small Cell
◽
Line Treatment
◽
Second Line
◽
Phase 2
◽
Small Cell Lung
◽
Phase 2 Study
Download Full-text
Apatinib Plus Vinorelbine in Second Line Treatment Failure Wildtype Advanced Non-Small Cell Lung Cancer (VICTOR): A Phase II Three-Dimensional Co-Culture Platforms-Guided Prospective Study
SSRN Electronic Journal
◽
10.2139/ssrn.3457407
◽
2019
◽
Author(s):
Xiangyu Zhang
◽
Yi Xiong
◽
Qing Xia
◽
Fang Wu
◽
Lingli Liu
◽
...
Keyword(s):
Lung Cancer
◽
Treatment Failure
◽
Prospective Study
◽
Small Cell Lung Cancer
◽
Phase Ii
◽
Three Dimensional
◽
Small Cell
◽
Line Treatment
◽
Second Line
◽
Small Cell Lung
Download Full-text
Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study
British Journal of Cancer
◽
10.1038/s41416-021-01356-3
◽
2021
◽
Author(s):
Ying Cheng
◽
Qiming Wang
◽
Kai Li
◽
Jianhua Shi
◽
Ying Liu
◽
...
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Small Cell
◽
Line Treatment
◽
Phase 2
◽
Small Cell Lung
◽
Double Blind
◽
Double Blind Placebo
◽
Phase 2 Study
Download Full-text
Cost-Effectiveness In The Second-Line Treatment Of Non-Small Cell Lung Cancer (Nsclc) In The Us
Value in Health
◽
10.1016/j.jval.2015.09.1174
◽
2015
◽
Vol 18
(7)
◽
pp. A457-A458
◽
Cited By ~ 1
Author(s):
C Graham
◽
H Knox
◽
LM Hess
◽
M Jen
◽
G Cuyun Carter
◽
...
Keyword(s):
Lung Cancer
◽
Cost Effectiveness
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Small Cell
◽
Line Treatment
◽
Second Line
◽
Small Cell Lung
◽
The Us
Download Full-text
Re‐Evaluating Progression in an Era of Progress: A Review of First‐ and Second‐Line Treatment Options in Anaplastic Lymphoma Kinase‐Positive Non‐Small Cell Lung Cancer
The Oncologist
◽
10.1634/theoncologist.2015-0396
◽
2016
◽
Vol 21
(6)
◽
pp. 755-761
◽
Cited By ~ 14
Author(s):
Emily H. Castellanos
◽
Leora Horn
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Anaplastic Lymphoma Kinase
◽
Treatment Options
◽
Small Cell
◽
Line Treatment
◽
Second Line
◽
Small Cell Lung
◽
Anaplastic Lymphoma
Download Full-text
Response to: Second-line treatment of non-small-cell lung cancer with wild-type EGFR status. What is the best approach?
Current Oncology
◽
10.3747/co.23.2955
◽
2016
◽
Vol 23
(2)
◽
pp. 160
◽
Cited By ~ 1
Author(s):
K.A. Ma
◽
G. Kasymjanova
◽
V. Cohen
◽
J. Agulnik
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Small Cell
◽
Line Treatment
◽
Second Line
◽
Wild Type
◽
Small Cell Lung
-
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close